Calidi Biotherapeutics, Inc. (CLDWW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

Calidi issued a warrant for 17.4 million shares at $0.23 exercise price to a single accredited investor, representing a significant equity dilution event that could materially impact existing shareholders upon exercise.
The warrant includes a vesting mechanism tied to up to $4 million in registered equity issuances by July 2026, suggesting the company is actively raising capital and may face additional dilution if the investor exercises this option.
The warrant is not exercisable until September 8, 2026, providing a 4-month window before potential dilution occurs, though the company could see interim capital infusions through the registered offering provision.
This private placement under Rule 506(b) indicates the company may be experiencing liquidity needs or funding requirements that necessitate dilutive financing rather than debt or other capital structures.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-02

Calidi Biotherapeutics is an emerging growth company, which could indicate potential upside but also higher risk.
The company is reducing the size of its board of directors from six to five members, likely to streamline decision-making.
The appointment of a new member to the audit committee suggests increased oversight and governance focus.

Filed: 2026-03-27

Calidi Biotherapeutics reported its Q4 and full-year 2025 financial results, showing strong revenue growth and improved profitability.
The company announced several recent corporate developments, including new partnerships and advancements in its pipeline of biotherapeutic products.
As an emerging growth company, Calidi Biotherapeutics may benefit from extended transition periods for adopting new accounting standards.

Filed: 2026-03-11

Calidi Biotherapeutics raised $6.03 million in a public offering, which will provide additional working capital and funding for general corporate purposes.
The company issued a variety of warrants, including Series J, K, and L warrants, which have the potential to provide additional future funding depending on warrant exercise.
The warrants include provisions for exercise price resets, which could benefit investors if the stock price declines over time.

Filed: 2026-02-10

Calidi Biotherapeutics, Inc. is an emerging growth company in the healthcare/biotech sector, indicating potential upside but also higher risk.
The company has made an updated presentation available on its website, which could provide investors with new information on the company's developments and strategies.
The 8-K filing does not indicate any material agreements, leadership changes, or earnings surprises, suggesting a relatively routine update from the company.

Filed: 2026-01-29

Calidi Biotherapeutics, Inc. provided preliminary unaudited financial information for fiscal year 2025, indicating the company is on track to meet its financial goals.
The company plans to submit an Investigational New Drug (IND) application by the end of 2026, which could be a significant milestone for the development of its therapies.
The 8-K filing includes forward-looking statements about the company's plans and initiatives for fiscal year 2026, which investors should closely monitor for updates.

Other reports for Calidi Biotherapeutics, Inc.

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.